BioSpace News Archive

Vor Biopharma today announced the presentation of new data from its novel cell therapy platform at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place in Washington D.C., from November 10-14, 2021.

Cardiff Oncology, Inc. (Nasdaq: CRDF), today announced that company management will present and participate in virtual 1x1 investor meetings at the Jefferies London Healthcare Conference.

Strand Therapeutics today announced that the company was awarded a Phase I Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI)

Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)

AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021

Arkstone Medical Solutions, the leading provider of proactive antimicrobial stewardship, is pleased to announce the appointment of Dr. Juan Carlos Gómez de la Torre Pretell as their new Director of Molecular Informatics.

SYNAPS Dx (SDx), announces that DISCERN™, the first autopsy-validated, highly accurate, minimally invasive test for the definitive diagnosis of AD versus other forms of non-AD dementias and those with AD and other degenerative pathologies, is the first AD test of its kind to earn Proprietary Laboratory Analyses (PLA) Code 206U and 207U.

AXIM Biotechnologies, Inc, an international healthcare solutions company targeting COVID-19 diagnostics and oncological research, announced their publication in the Journal of Clinical Virology describing the development of a rapid test to measure levels of neutralizing antibodies to SARS-CoV-2.

Abbott and the American Diabetes Association® announced the launch of their first joint community health partnership.

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, announced that it has completed an amendment to Pulmatrix’s agreement with Cipla Technologies, LLC for the development and commercialization of Pulmazole.